Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc Sage FutureCast: An R&D and Portfolio Review Transcript

Sep 10, 2020 / 01:00PM GMT
Release Date Price: €43.79 (+3.99%)
Jeff Boyle
Sage Therapeutics, Inc. - Investor Contact

Good morning, everyone, and thanks for joining the Second Annual Sage FutureCast call. I'm Jeff Boyle, Head of Investor Relations at Sage. Before we begin, I encourage everyone to go to the investor and media section of our website at sagerx.com, where you can find the press release related to today's call as well as slides that we will discuss.

I'd like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please consult the risk factors discussed in our SEC filings for additional details.

We will begin the call with prepared remarks by Dr. Jim Doherty, our Chief Research Officer; Dr. Rob Lasser, Vice President, Late Stage Development; Dr. Helen Colquhoun, Vice President, Early Development; Dr. Mike Quirk, Vice President, Pharmacology; Dr. Aaron Koenig, Medical Director, Early Development; Dr. Steve Kanes, our Chief Medical Officer; and then finally, Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot